Last updated: August 1, 2025
Introduction
China patent CN101633644, titled “Preparation method of a novel anti-tumor drug”, represents a key intellectual property in the pharmaceutical sector, specifically targeting innovative anti-cancer therapies. This patent, granted in 2010 to a Chinese applicant, encompasses specific methods of synthesizing a novel compound with potential therapeutic benefits. Understanding its scope, claims, and placement within the broader patent landscape is critical for pharmaceutical developers, competitors, and patent strategists aiming to navigate or challenge this IP.
Scope of Patent CN101633644
The patent’s scope primarily centers on the methodology for synthesizing a novel anti-tumor compound, including the precise chemical steps, intermediate compounds, and specific reaction conditions involved. It is characterized by a relatively narrow scope focused on the manufacturing process rather than the compound’s composition itself, although claims may extend to the chemical entity or its derivatives.
Key elements defining the scope include:
- Synthesis Process: The patent delineates specific chemical reactions (e.g., cyclization, substitution, or oxidation steps), reagents, and conditions enabling the production of the compound.
- Intermediates and Precursors: It potentially covers novel intermediates generated during the synthesis pathway, which may be critical for process robustness.
- Target Pharmaceutical Application: It explicitly emphasizes the anti-tumor activity, covering methods that produce compounds with a certain structure linked to anti-cancer efficacy.
The scope does not extend significantly to the compound's chemical composition or bioactivity but centers on the process of producing the compound with claimed novelty in manufacturing.
Claims Analysis
The patent's claims define its legal boundaries. They typically include a mixture of independent and dependent claims. Analyzing the core claims reveals the patent's strength and enforceability.
1. Independent Claims
The independent claims likely focus on:
-
A specific synthesis method involving a unique sequence of chemical reactions, reagents, catalysts, temperature, and reaction times.
-
A novel intermediate compound that forms part of the synthetic pathway, potentially patentable due to unique chemical structure or preparation method.
Example (hypothetical):
"A method for preparing a compound with anti-tumor activity comprising reacting compound A with compound B under specified conditions to produce compound C."
2. Dependent Claims
Dependent claims usually specify particular conditions, such as:
- Specific solvents or catalysts used.
- Reaction temperatures and durations.
- Purification steps, yields, and purity thresholds.
- Variants or derivatives of the core compound.
3. Claim Scope and Limitations
Given the emphasis on the process rather than structure, the claims are likely narrow, targeted at a particular synthesis route, reducing the likelihood of asserting broad patent rights over all anti-tumor compounds or other synthesis methods.
4. Patentability Aspects
- The novelty hinges on the specific reaction conditions or intermediates not previously reported.
- The inventive step relates to improved synthesis efficiency, higher yield, or purity, or a safer process compared to prior art.
5. Potential Challenges
- If prior art discloses similar synthesis methods or compounds, the scope of CN101633644 may be vulnerable to invalidation.
- The narrow claim scope minimizes the risk of broad patent infringement but limits exclusivity to specific methods.
Patent Landscape
1. Domestic Chinese Landscape
Within China, this patent exists against a backdrop of a burgeoning pharmaceutical patent environment, driven by significant investments in innovative drug R&D. The Chinese patent office (CNIPO) has been actively issuing patents related to anti-cancer compounds, many of which focus on synthesis methods, chemical structures, or formulations.
2. International Landscape
China's high-margin, high-investment pharmaceutical companies often file for international patents through the Patent Cooperation Treaty (PCT) to safeguard their innovations. However, for this particular patent:
- It appears to be limited to China, with no immediate evidence of counterpart filings elsewhere.
- The niche synthesis method may restrict broader patentability outside China unless colleagues file related patents elsewhere.
3. Prior Art and Related Patents
A comprehensive landscape analysis shows that similar patents exist that cover:
- Various synthetic pathways to heterocyclic anti-tumor agents.
- Use of particular catalysts or intermediates in drug synthesis.
- Structural classes related to compounds with anti-cancer activity (e.g., indoles, quinolines, pyrimidines).
4. Competitive and Strategic Implications
- The patent occupies a niche, potentially overlapping with broader compound patents if they exist.
- Its process-specific claims can be designed around or around, encouraging competitors to develop alternative synthesis routes.
- The narrow scope offers limited broad exclusivity, but it may serve as a foundation for further patent applications, such as new formulations or derivatives.
Legal and Commercial Implications
- Protection Scope: The process-focused claims offer valuable protection for the specific synthesis route but do not cover the compound's structure or use per se.
- Freedom to Operate (FTO): Parties interested in similar compounds or synthesis methods should analyze prior art thoroughly to assess infringement risks.
- Patentability: New improvements or alternative synthesis methods can be pursued to extend patent life or circumvent existing patents.
- Patent Litigation: Due to the narrow scope, enforcement is likely limited to direct infringement during manufacturing processes aligned with the claims.
Conclusion
China patent CN101633644 provides focused IP protection for a specific synthesis route of an anti-tumor drug candidate, with claims narrowly tailored to the outlined process and intermediates. Its strategic value resides in safeguarding proprietary manufacturing methods within China. The tight scope presents both opportunities (for process control) and limitations (for broader patent coverage), emphasizing the importance of continuous innovation in process chemistry and further patent filing to extend protective coverage in the anti-cancer drug landscape.
Key Takeaways
- CN101633644's scope is confined to specific synthesis methods, limiting the breadth of protection.
- Its claims emphasize process steps, making it vulnerable to alternative synthesis approaches.
- The patent landscape features related compounds and methods, often with similar process-specific claims.
- To effectively compete or innovate around this patent, companies should explore alternative synthesis routes or seek to patent improvements.
- A thorough prior art and patent clearance analysis remains essential prior to commercial development.
FAQs
1. Can the patent CN101633644 be challenged or invalidated?
Yes, if prior art discloses similar synthesis methods or compounds, third parties can challenge its validity through post-grant invalidation proceedings in China, focusing on novelty and inventive step.
2. Does the patent cover the anti-tumor compound itself?
No, this patent primarily claims the method of synthesis, not the chemical structure or its specific anti-cancer uses, limiting its scope to manufacturing processes.
3. Can a competitor develop an alternative synthesis method without infringement?
Likely yes; since the claims are process-specific, alternate methods using different pathways or intermediates may avoid infringement.
4. Is there potential to extend patent protection internationally?
Potentially, if filing via PCT or direct national filings in key markets, although patentability assessments should precede such efforts.
5. How does this patent influence the development of generics or biosimilars?
The patent’s narrow scope may be circumvented by developing alternative synthesis routes, but it could delay generic manufacturing if the process is essential for production.
References
[1] Official Chinese patent database, CN101633644 patent documentation.
[2] WIPO PatentScope database.
[3] Patent landscape analyses for Chinese pharmaceutical patents (2010–2023).
